{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:42:38Z","timestamp":1791668558624,"version":"4.3.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Young Scientists Fund of the National Natural Science Foundation of China","award":["32301236"],"award-info":[{"award-number":["32301236"]}]},{"name":"the Young Scientists Fund of the National Natural Science Foundation of China","award":["32201215"],"award-info":[{"award-number":["32201215"]}]},{"name":"the Young Scientists Fund of the National Natural Science Foundation of China","award":["32201212"],"award-info":[{"award-number":["32201212"]}]},{"name":"Shanghai Sailing Program","award":["23YF1402800"],"award-info":[{"award-number":["23YF1402800"]}]},{"name":"Shanghai Sailing Program","award":["22YF1403100"],"award-info":[{"award-number":["22YF1403100"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003154"],"award-info":[{"award-number":["82003154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372669"],"award-info":[{"award-number":["82372669"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32330062"],"award-info":[{"award-number":["32330062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303200"],"award-info":[{"award-number":["2022YFA1303200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["22XD1420100"],"award-info":[{"award-number":["22XD1420100"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Major Project of Special Development Funds of Zhangjiang National Independent Innovation Demonstration Zone","award":["ZJ2019\u2010ZD\u2010004"],"award-info":[{"award-number":["ZJ2019\u2010ZD\u2010004"]}]},{"name":"the Science and Technology Commission of Shanghai Municipality","award":["2017SHZDZX01"],"award-info":[{"award-number":["2017SHZDZX01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy is the first-line therapy for esophageal squamous cell carcinoma (ESCC), yet many patients do not respond due to drug resistance and the lack of reliable predictive markers. We collected 73 ESCC patients (including discovery cohort and validation cohort) without immune thrombocytopenia and undergoing anti-PD1 immunotherapy. Proteomic and phosphoproteomic analysis of 73 ESCC treatment-naive samples by mass spectrometry-based label-free quantification were applied to explore the potential resistant and sensitive mechanisms, and identify predictive markers of ESCC immunotherapy. Comparative analysis found the pathways related to immune and mitochondrial functions were associated with ESCC immunotherapy sensitivity; while platelet activation bioprocess showed negative correlation with CD8+\u2009T cells and related to ESCC immunotherapy non-sensitivity. Finally, we identified 10 ESCC immunotherapy predictive biomarkers with high accuracy (\u2265\u20090.90) to predict the immunotherapeutic response, which was validated in the independent cohort.<\/jats:p>","DOI":"10.1186\/s13045-024-01534-9","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:01:37Z","timestamp":1710511297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers"],"prefix":"10.1186","volume":"17","author":[{"given":"Fahan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohua","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanxian","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"10125","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"9864","key":"1534_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400\u201312.","journal-title":"Lancet"},{"issue":"3","key":"1534_CR3","doi-asserted-by":"publisher","first-page":"e004291","DOI":"10.1136\/jitc-2021-004291","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Yang Y, Liu ZC, Fu XL, Cai XY, Li HX, Zhu L, Shen Y, Zhang H, Sun YF, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"1534_CR4","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.2023.41.16_suppl.4049","volume":"41","author":"ZH Lu","year":"2023","unstructured":"Lu ZH, Zhao J, Yang Z, Li N, Wang JS, Yuan SH, Wang YS, Li SY, Ran FM, Ji YH, et al. Effectiveness and safety of camrelizumab in advanced esophageal cancer: a prospective multicenter observational cohort studies (ESCORT-RWS). J Clin Oncol. 2023;41(16):4049\u20134049.","journal-title":"J Clin Oncol"},{"key":"1534_CR5","doi-asserted-by":"publisher","first-page":"803133","DOI":"10.3389\/fonc.2021.803133","volume":"11","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: Where do we stand? Front Oncol. 2021;11:803133.","journal-title":"Front Oncol"},{"issue":"1","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"key":"1534_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu ZC, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:1\u201314.","journal-title":"Genome Biol"},{"issue":"4","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"499-+","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi HY, Kelly DW, Patel N, et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2022;40(4):499-+.","journal-title":"Nat Biotechnol"},{"issue":"7693","key":"1534_CR9","doi-asserted-by":"publisher","first-page":"544-+","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang YL, Kadel EE, Koeppen H, Astarita JL, Cubas R, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544-+.","journal-title":"Nature"},{"issue":"25","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"issue":"D1","key":"1534_CR11","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu SF, Yang CY, Bai MZ, Shu KX, Li KL, Zhang GQ, Jin Z, He FC, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47(D1):D1211\u20137.","journal-title":"Nucleic Acids Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01534-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01534-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01534-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T14:06:12Z","timestamp":1710511572000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01534-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01534-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was compliant with the ethical standards of Helsinki Declaration and was approved by the institutional review board of\u00a0Shanghai Chest Hospital. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}